Antibody avidity maturation favors SARS-CoV-2 convalescents over vaccinated individuals granting breadth in neutralizability and tolerance against variants
View ORCID ProfileYu Nakagama, View ORCID ProfileKatherine Candray, Natsuko Kaku, View ORCID ProfileYuko Komase, Maria-Virginia Rodriguez-Funes, Rhina Dominguez, View ORCID ProfileTomoya Tsuchida, Hiroyuki Kunishima, Etsuko Nagai, Eisuke Adachi, Dieudonné Mumba Ngoyi, Mari Yamasue, Kosaku Komiya, Kazufumi Hiramatsu, Naoto Uemura, View ORCID ProfileYuki Sugiura, View ORCID ProfileMayo Yasugi, Yuka Yamagishi, View ORCID ProfileHiroshige Mikamo, Satoshi Shiraishi, Takehiro Izumo, Sachie Nakagama, Chihiro Watanabe, View ORCID ProfileYuko Nitahara, Evariste Tshibangu-Kabamba, Hiroshi Kakeya, View ORCID ProfileYasutoshi Kido
doi: https://doi.org/10.1101/2022.09.19.22280078
Yu Nakagama
aDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
bResearch Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Katherine Candray
aDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
bResearch Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
cCentro Nacional de Investigaciones Científicas de El Salvador (CICES), San Salvador, El Salvador
Natsuko Kaku
aDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
bResearch Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Yuko Komase
dDepartment of Respiratory Internal Medicine, St. Marianna University, Yokohama Seibu Hospital, Yokohama, Japan
Maria-Virginia Rodriguez-Funes
eNational Rosales Hospital, San Salvador, El Salvador
Rhina Dominguez
fEl Salvador National Institute of Health, San Salvador, El Salvador
Tomoya Tsuchida
gDivision of General Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Hiroyuki Kunishima
hDepartment of Infectious Diseases, St. Marianna University School of Medicine, Kawasaki, Japan
Etsuko Nagai
iDepartment of Infectious Diseases and Applied Immunology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Eisuke Adachi
iDepartment of Infectious Diseases and Applied Immunology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Dieudonné Mumba Ngoyi
jInstitut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo
Mari Yamasue
kDepartment of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Oita, Japan
Kosaku Komiya
kDepartment of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Oita, Japan
Kazufumi Hiramatsu
kDepartment of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Oita, Japan
Naoto Uemura
kDepartment of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Oita, Japan
Yuki Sugiura
lCenter for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Mayo Yasugi
mGraduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan
nAsian Health Science Research Institute, Osaka Metropolitan University, Osaka, Japan
oOsaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan
Yuka Yamagishi
pDepartment of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan
Hiroshige Mikamo
pDepartment of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan
Satoshi Shiraishi
qDepartment of Respiratory Medicine, Osaka City Juso Hospital, Osaka, Japan
Takehiro Izumo
rDepartment of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan
Sachie Nakagama
aDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
bResearch Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Chihiro Watanabe
aDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
bResearch Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Yuko Nitahara
aDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
bResearch Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Evariste Tshibangu-Kabamba
aDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
bResearch Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Hiroshi Kakeya
bResearch Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
sDepartment of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Yasutoshi Kido
aDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
bResearch Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Article usage
Posted September 19, 2022.
Antibody avidity maturation favors SARS-CoV-2 convalescents over vaccinated individuals granting breadth in neutralizability and tolerance against variants
Yu Nakagama, Katherine Candray, Natsuko Kaku, Yuko Komase, Maria-Virginia Rodriguez-Funes, Rhina Dominguez, Tomoya Tsuchida, Hiroyuki Kunishima, Etsuko Nagai, Eisuke Adachi, Dieudonné Mumba Ngoyi, Mari Yamasue, Kosaku Komiya, Kazufumi Hiramatsu, Naoto Uemura, Yuki Sugiura, Mayo Yasugi, Yuka Yamagishi, Hiroshige Mikamo, Satoshi Shiraishi, Takehiro Izumo, Sachie Nakagama, Chihiro Watanabe, Yuko Nitahara, Evariste Tshibangu-Kabamba, Hiroshi Kakeya, Yasutoshi Kido
medRxiv 2022.09.19.22280078; doi: https://doi.org/10.1101/2022.09.19.22280078
Antibody avidity maturation favors SARS-CoV-2 convalescents over vaccinated individuals granting breadth in neutralizability and tolerance against variants
Yu Nakagama, Katherine Candray, Natsuko Kaku, Yuko Komase, Maria-Virginia Rodriguez-Funes, Rhina Dominguez, Tomoya Tsuchida, Hiroyuki Kunishima, Etsuko Nagai, Eisuke Adachi, Dieudonné Mumba Ngoyi, Mari Yamasue, Kosaku Komiya, Kazufumi Hiramatsu, Naoto Uemura, Yuki Sugiura, Mayo Yasugi, Yuka Yamagishi, Hiroshige Mikamo, Satoshi Shiraishi, Takehiro Izumo, Sachie Nakagama, Chihiro Watanabe, Yuko Nitahara, Evariste Tshibangu-Kabamba, Hiroshi Kakeya, Yasutoshi Kido
medRxiv 2022.09.19.22280078; doi: https://doi.org/10.1101/2022.09.19.22280078
Subject Area
Subject Areas
- Addiction Medicine (316)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2298)
- Dermatology (202)
- Emergency Medicine (371)
- Epidemiology (11625)
- Forensic Medicine (10)
- Gastroenterology (683)
- Genetic and Genomic Medicine (3629)
- Geriatric Medicine (341)
- Health Economics (622)
- Health Informatics (2332)
- Health Policy (919)
- Hematology (336)
- HIV/AIDS (758)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3391)
- Nursing (193)
- Nutrition (512)
- Oncology (1777)
- Ophthalmology (526)
- Orthopedics (211)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1014)
- Primary Care Research (410)
- Public and Global Health (6022)
- Radiology and Imaging (1238)
- Respiratory Medicine (814)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (143)